B7 family members and their receptors play a central role in the regulation of T‐cell responses through T‐cell co‐stimulation and co‐inhibition pathways that constitute attractive targets for the development of immunotherapeutic drugs. In this study, we report that VSIG‐3/IGSF11 is a ligand of B7 family member VISTA/PD‐1H and inhibits human T‐cell functions through a novel VSIG‐3/VISTA pathway. An extensive functional ELISA binding screening assay reveals that VSIG‐3 binds to the new B7 family member VISTA but does not interact with other known members of the B7 family. Under the same experimental conditions, we did not observe any significant interaction between VSIG‐8 and VISTA. In addition, VSIG‐3 inhibits human T‐cell proliferation in the presence of T‐cell receptor signaling. Furthermore, VSIG‐3 significantly reduces cytokine and chemokine production by human T cells including IFN‐γ, IL‐2, IL‐17, CCL5/Rantes, CCL3/MIP‐1α, and CXCL11/I‐TAC. Anti‐VISTA neutralization antibodies attenuate the binding of VSIG‐3 and VISTA, as well as VSIG‐3‐induced T‐cell inhibition. Hence, we have identified a novel ligand for VISTA that is able to inhibit human T‐cell proliferation and cytokine production. This unique VSIG‐3/VISTA co‐inhibitory pathway may provide new strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may aid in the design of better vaccines.